• Ford Robert B, Chairman and CEO of Abbott Laboratories, purchased 18,800 shares, indicating strong confidence in the company's future.
• Despite a decline in its stock price, Abbott Laboratories is rated as a 'Buy', with strong growth in its Medical Devices segment.
• The company forecasts a 7% increase in sales and a 10% growth in EPS for 2025, driven by innovation and a rebound in the Nutrition segment.

Abbott Laboratories, listed on the NYSE under the symbol ABT, is a global healthcare company known for its diverse range of products, including medical devices, diagnostics, and nutritional products. The company competes with other major healthcare firms, focusing on innovation and growth in its key segments. Recently, Abbott's stock has faced some challenges, but it remains a strong player in the industry.

On January 23, 2026, Ford Robert B, the Chairman and CEO of Abbott Laboratories, purchased 18,800 common shares at approximately $107.13 each. This transaction increased his total ownership to 216,203 shares. Despite the recent decline in Abbott's stock price, this move signals confidence in the company's future prospects and potential for growth.

Abbott Laboratories has been rated as a 'Buy' despite a recent decline in its stock price. The drop was primarily due to weaknesses in its Nutrition segment and a decrease in COVID-19 diagnostics. However, the company's Medical Devices segment, particularly its Continuous Glucose Monitoring (CGM) products, continues to show strong double-digit growth, which helps to counterbalance the challenges in the Nutrition sector.

The current stock price of ABT is $107.42, reflecting a decrease of 1.19, or approximately -1.10% in percentage terms. Today, the stock has traded between a low of $106.08 and a high of $110.05. Over the past year, ABT has reached a high of $141.23 and a low of $105.78. The company's market capitalization stands at approximately $186.96 billion. The trading volume for ABT on the NYSE is 21,703,521 shares.

Abbott Laboratories is forecasting a 7% increase in sales and a 10% growth in earnings per share (EPS) for 2025. This optimistic outlook is supported by ongoing innovation and a return to normalcy in the Nutrition segment. Despite recent challenges, the company's strong performance in the Medical Devices segment and strategic initiatives position it well for future growth.